AssetMark’s AnaptysBio ANAB Stock Holding History
Bought
Maintained
Sold
Other funds holding ANAB
AssetMark's ANAB Position: Q3 2026 in Review
AssetMark increased its AnaptysBio (ANAB) stake by 17% in Q3 2026, buying an estimated $339 and bringing the position to 42 shares worth $2.11K. The position accounts for ﹤0.01% of the portfolio, ranked #3034.
AssetMark first reported a position in ANAB in Q2 2025 and has held it in 6 quarters since. The position peaked at $2.43K in Q2 2026. 160 funds tracked by Wall St. Rank hold ANAB as of Q3 2026.
- AssetMark held 42 shares of AnaptysBio worth $2.11K as of Q3 2026.
- AssetMark bought 6 AnaptysBio shares in Q3 2026, an estimated $339.
- AnaptysBio made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3034 holding.
- AssetMark first reported a position in AnaptysBio in Q2 2025 and has held it in 6 quarters since.
- AssetMark's AnaptysBio position peaked at $2.43K in Q2 2026.
- 160 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.